RE:RE:RE:RE:RE:RE:“Second mouse gets the cheese “ January 03, 2024 - Goldman Sachs is planning to make a splash in the life sciences sector, taking in $650 million for its first fund aimed at the drug development space.
The size of the West Street Life Sciences I fund, which overshot its original target, makes it one of the largest first-time private life sciences growth funds, Goldman Sachs Asset Management claimed in a Jan. 3 release. The $650 million in equity commitments was drawn from a “global, diverse group of institutional, strategic and high net worth investors."
“Goldman Sachs Asset Management has identified several themes of fundamental innovation as well as structural shifts that we believe will drive significant growth in the coming decades,” the firm said in the release. “These themes include precision medicine, genetic medicine, cell therapy, immunotherapy, synthetic biology, and artificial intelligence.”
Amit Sinha, head of the Life Sciences Investing Group, said the sector is entering a “golden era of innovation.”
“We believe the current environment provides an attractive opportunity for investing in the next generation of leading life sciences companies,” Sinha added